Severe acute respiratory syndrome: Report of treatment and outcome after a major outbreak

Thorax

Volumn 59, Issue 5, 2004, Pages 414-420

  Sung, J J Y ^b   Wu, A ^b   Joynt, G M ^b   Yuen, K Y ^c   Lee, N ^b   Chan, P K S ^b   Cockram, C S ^b   Ahuja, A T ^b   Yu, L M ^b   Wong, V W ^b   Hui, D S C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEFOTAXIME; CLARITHROMYCIN; CORTICOSTEROID; HYDROCORTISONE; LEVOFLOXACIN; METHYLPREDNISOLONE; OSELTAMIVIR; OXYGEN; PREDNISOLONE; RIBAVIRIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG RESPONSE; EPIDEMIC; FEMALE; FEVER; HEMOLYTIC ANEMIA; HONG KONG; HOSPITAL DISCHARGE; HUMAN; INFLUENZA; INTENSIVE CARE UNIT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DISEASE OUTBREAKS; FEMALE; GLUCOCORTICOIDS; HONG KONG; HUMANS; INTENSIVE CARE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

EID: 2442581595     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2003.014076     Document Type: Article

References (36)

1. Lee N, Hui DS, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
2. Update: outbreak of severe acute respiratory syndrome - worldwide 2003. MMWR Morb Mort Wkly Rep 2003;52:241-8.
3. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263-70.
4. Drosten C, Gunther S, Preiser W, et al. Identification of a novel Coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
5. Ksiazek TG, Erdman D, Goldsmith CS, et al. A Novel Coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66.
6. Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS) updated interim U.S. case definition. http://www.cdc.gov/ncidod/ sars/casedefinition.htm (accessed 20 April 2003).
7. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
8. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.
9. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. Am J Respir Crit Care Med 1995;153:1711-25.
10. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
11. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72.
12. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003;9:713-7.
13. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9.
14. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361:1773-8.
15. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophage by influenza A (H5N1) virus: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-7.
16. Van Reeth K, Van Gucht S, Pensaret M. In vivo studies on cytokines involvement during acute viral respiratory infection of swine: troublesome but rewarding. Vet Immun Immunopathol 2002;87:161-8.
17. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-93.
18. Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. Nature 2003;423:4.
19. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
20. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615-7.
21. Nhong NS, Zeng GQ. Our strategies for fighting severe acute respiratory syndrome. Am J Respir Crit Care Med 2003;168:7-9.
22. Ho JC, Ooi GC, Mok TY, et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003, Epub ahead of print URL: http://ajrccm.atsjournals.org/cgi/ reprint/200306-766OCv1.pdf.
23. Wong KT, Antonio GE, Hui DS, et al. Thin section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 2003;228:395-400.
24. Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001;161:158-64.
25. Fisman DN. Hemophagocytic syndrome and infection. Emerg Infect Dis 2000;6:60-8.
26. Lai KN, Leung JC, Metz CN, et al. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol 2003;199:496-508.
27. Laskin OL, Longstreth JA, Hart CC, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharm Ther 1987;41:543-55.
28. Roberts RB, Laskin OL, Laurence J, et al. Ribavirin pharmcodynamics in high-risk patiens for acquired immunodeficiency syndrome. Clin Pharm Ther 1987;42:365-73.
29. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287:2391-405.
30. Hansson LO, Lindquist L. C-reactive protein: its role in the diagnosis and follow-up of infectious diseases. Curr Opin Infect Dis 1997;10:196-201.
31. Gabay C, Kushner I. Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
32. Gattinoni L, Tognoni G, Pesenti A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001;345:568-73.
33. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003;349:507-8.
34. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-9.
35. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-404.
36. Ruan YJ, Wei CL, Ee LA, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779-85.